



DRUG DISCOVERY

## **Innovative Strategies and Models for R&D Success**

The evolving networked pharma company

By Dr CL Barton

 Table of Contents

## **Dr Cheryl L Barton**

Dr CL Barton has over 10 years' practical pharmaceutical research experience with a leading pharmaceutical company and Pan-European Pharmaceutical analyst with a European Bank.

Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector.

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Innovative Strategies and Models for R&D Success

<b>Executive Summary</b>	<b>12</b>	
Evolution of R&D Strategies: A Moving Target	12	
Private-Public Partnerships	13	
Private-Federal Partnerships	14	
Outsourcing: Home Territories	15	
Offshoring: Emerging Markets	16	
In-licensing: Virtual Pharma Models	17	
R&D Spin Offs	18	
Internal Reorganization, Market Trends & Conclusions	19	
<b>Chapter 1</b>	<b>Evolution of R&amp;D Strategies: A Moving Target</b>	<b>22</b>
Summary		22
Introduction		23
Trends in R&D		24
The Evolving Network R&D Model		30
<b>Chapter 2</b>	<b>Public-Private Partnerships</b>	<b>34</b>
Summary		34
What is a PPP?		35
Open-source R&D		35
Applications to the pharma industry		37
Alliance Case Studies		42
Case Study: GlaxoSmithKline and the MMV, MVI and GATB		42
Case Study: Bayer and the TB Alliance		44
‘Crowd’ Sourcing Case Studies		45
Case Study: InnoCentive & Scienteur Corporation		45
Technology Transfer Case Studies		45
Case Study: Technology transfer PPPs with NIH		45
Conclusions		47

## **Chapter 3                      Private-Federal Partnerships                      50**

<b>Summary</b>	<b>50</b>
<b>Cooperative Research &amp; Development agreements</b>	<b>51</b>
Small Business Innovation Research Programs	52
Regulation enabling technology transfer	52
Technology alliances	54
The Cooperate Research (CORE) database (US alliances)	54
The Cooperate Research (CORE) database (International alliances)	55
<b>Publicly funded medicines</b>	<b>56</b>
Applications to the pharma industry	58
<b>Technology transfer case studies</b>	<b>58</b>
Case Study: Taxol technology transfer NIH to BMS	58
Case Study: Erythropoietin technology transfer to Amgen and Johnson & Johnson	61
Case Study: FluMist technology transfer NIAID to Aviron	62
Case Study: Velcade technology transfer from NIH to Millennium Pharmaceuticals	63
<b>Conclusions</b>	<b>64</b>

## **Chapter 4                      Outsourcing: within mature markets                      68**

<b>Summary</b>	<b>68</b>
<b>Introduction</b>	<b>69</b>
<b>Contract Research Organizations</b>	<b>70</b>
<b>Outsourcing services</b>	<b>71</b>
<b>Investment in contract research</b>	<b>73</b>
<b>Balancing Outsourcing Portfolio: Home &amp; Abroad</b>	<b>74</b>
Shift from North America & Western European Contract Services	75
Shift in customer base	78
Shift in partnerships	79
<b>Strategic Partnerships &amp; Risk Sharing</b>	<b>79</b>
<b>Strategic partnerships case studies</b>	<b>81</b>
Case Study: Accenture & Wyeth	81
Case Study: Functional service providers & Pfizer	81
<b>Risk sharing case studies</b>	<b>82</b>
Case Study: NovaQuest & Eli Lilly & ProStrakan	82
Case Study: PPD & Ranbaxy/Takeda/ALZA/Accentia Biopharmaceuticals	83
<b>Conclusions</b>	<b>84</b>

## **Chapter 5                      Offshoring: emerging markets                      88**

<b>Summary</b>	<b>88</b>
<b>Introduction</b>	<b>89</b>
<b>Offshore outsourcing</b>	<b>90</b>
Investment in offshore contract research.	91
<b>Outsourcing services in China</b>	<b>93</b>
<b>Contract R&amp;D in China</b>	<b>94</b>
<b>Contract clinical research in China</b>	<b>95</b>
Leading R&D players in China	96
<b>R&amp;D Contract Services case study</b>	<b>99</b>
Case Study: WuXi & AstraZeneca	99
<b>Risk Sharing Agreement case studies</b>	<b>100</b>
Case Study: Hutchison MediPharma & Eli Lilly, Merck KGaA and Procter & Gamble	100
<b>Research Collaboration case studies</b>	<b>101</b>
Case Study: Chemizon & Takeda	101
Case Study: Sunway Biotech & Genzyme	101
Case Study: Sanofi-Aventis & the Chinese Academy of Medical Sciences.	102
<b>Joint venture case studies</b>	<b>102</b>
Case Study: Charles River Laboratories & Shanghai BioExplorer	102
Case Study: Eli-Lilly's Asian Ventures	103
<b>Key Issues in China</b>	<b>103</b>
<b>Outsourcing services in India</b>	<b>104</b>
<b>Contract R&amp;D in India</b>	<b>105</b>
<b>Contract clinical research in India</b>	<b>106</b>
<b>Leading R&amp;D players in India</b>	<b>107</b>
<b>Risk sharing agreements case studies</b>	<b>109</b>
Case Study: Advinus & Merck & Co.	109
Case Study: Aurigene & Merck Serono	109
Case Study: Dr Reddy Laboratories & ClinTec International	109
Case Study: Ranbaxy & GlaxoSmithKline/Merck & Co.	110
Case Study: Nicholas Piramil India Ltd / Eli Lilly and Merck & Co.	110
<b>Research partnership case studies</b>	<b>111</b>
Case Study: Jubilant Biosys & Amgen	111
Case Study: Syngene & Bristol-Myers Squibb	112
Case Study: GVK Bio & Wyeth	112
Case Study: Dr Reddy & RheoSciences	112
Case Study: Bristol Myers Squibb & Accenture	113
<b>Product in-licensing case studies</b>	<b>113</b>
Case Study: Glenmark Pharma & Eli Lilly	113
Case Study: Glenmark Pharma & Forest Labs	114
<b>Key issues in India</b>	<b>114</b>
<b>Outsourcing services in Russia</b>	<b>114</b>

<b>Contract R&amp;D in Russia</b>	<b>115</b>
<b>Contract clinical research in Russia</b>	<b>115</b>
<b>Leading R&amp;D players in Russia</b>	<b>117</b>
<b>Research collaboration case studies</b>	<b>120</b>
Case Study: Chembridge & Pfizer	120
Case Study: ChemDiv & Schering-Plough	120
<b>Key issues in Russia</b>	<b>121</b>
<b>Conclusions</b>	<b>122</b>

## **Chapter 6                      In-licensing: Virtual Pharma & Technology Aggregators                      126**

<b>Summary</b>	<b>126</b>
<b>Introduction</b>	<b>127</b>
<b>Virtual pharma companies and technology aggregators</b>	<b>128</b>
<b>Virtual pharma models</b>	<b>131</b>
<b>Virtual pharma models evolved from the pharma industry</b>	<b>132</b>
Case Study: Fulcrum Pharma plc	132
Case Study: Chorus	133
Case Study: TAP Pharmaceuticals	135
<b>Developing novel compounds case studies</b>	<b>135</b>
Case Study: Concordia Pharmaceuticals	135
Case Study: Celtic Pharma LCC	136
Case Study: VDDI Pharmaceuticals	137
<b>Repositioning old compounds case studies</b>	<b>139</b>
Case Study: AGI Therapeutics	139
Case Study: Arachnova Ltd	140
<b>Conclusions</b>	<b>141</b>

## **Chapter 7                      R&D spin offs                      144**

<b>Summary</b>	<b>144</b>
<b>The motivation behind R&amp;D spin offs</b>	<b>145</b>
<b>Pharma R&amp;D spin offs</b>	<b>147</b>
Case Study: AstraZeneca & Albireo	147
Case Study: Pfizer & Esperion	148
Case Study: Sanofi-Aventis & Novexel	150
Case Study: Roche & Basilea	151
<b>CRO R&amp;D spin offs</b>	<b>152</b>
Case Study: Ranbaxy Life Science Research Ltd & Daiichi	152
Case Study: Sun Pharma Advance Research Company Ltd	153
Case Study: NPIL pharma R&D de-merger	154

Conclusions	155
<b>Chapter 8</b>	
<b>Internal reorganization, market trends and conclusions</b>	<b>158</b>
<b>Summary</b>	<b>158</b>
<b>Introduction</b>	<b>159</b>
<b>Internal Reorganization</b>	<b>160</b>
<b>Large pharma R&amp;D models</b>	<b>161</b>
AstraZeneca	161
GlaxoSmithKline	164
Pfizer	168
Roche	171
<b>Emerging Market Trends</b>	<b>174</b>
<b>A complex R&amp;D process</b>	<b>174</b>
<b>A shift in R&amp;D focus &amp; attrition rates</b>	<b>177</b>
<b>A shift in therapeutic focus</b>	<b>179</b>
<b>Fragmentation of the industry</b>	<b>183</b>
<b>Geographical alignment of the industry</b>	<b>183</b>
<b>Conclusions</b>	<b>184</b>
<b>Index</b>	<b>187</b>
<b>Glossary</b>	<b>188</b>
<b>Bibliography &amp; Endnotes</b>	<b>191</b>

# List of Figures

Figure 1.1:	Pharma R&D spend and trial costs, 2004-2009e	24
Figure 1.2:	Global R&D spending by development phase (\$bn), 2007	25
Figure 1.3:	Biotech R&D spend and funding (\$bn), 2004-2009e	26
Figure 1.4:	Biotech R&D spend and funding (\$bn), 2001-2007	26
Figure 1.5:	Cost to develop a new biopharmaceutical (2005 \$m)	27
Figure 1.6:	Origin of New US drug approvals, 2000-2006	30
Figure 1.7:	Migration from traditional to an externally driven R&D platform	31
Figure 2.8:	R&D models A) Traditional approach and B) PPP approach	36
Figure 2.9:	PPPs - neglected disease projects	40
Figure 2.10:	PPP Developmental timelines	42
Figure 2.11:	Portfolio of the MMV	43
Figure 3.12:	CORE - technology alliances (number of alliances), 1985-2003	54
Figure 3.13:	Global and US-based technology alliances (number of alliances), 1985-2003	55
Figure 3.14:	Global technology alliances by region (number of alliances), 1985-2003	56
Figure 3.15:	FluMist developmental timelines	63
Figure 4.16:	Outsourcing Services	71
Figure 4.17:	Global Expenditure on R&D and Contract Research	73
Figure 4.18:	Pharma R&D Expenditure and spend on contract services by Phase, 2007	74
Figure 4.19:	Three Stages of CRO Evolution	79
Figure 4.20:	Strategic Outsourcing	80
Figure 5.21:	Areas for offshore contracting	90
Figure 5.22:	Average global clinical trial cost by region (\$ per patient), 2006	92
Figure 5.23:	Indexed clinical trial costs by country compared to the US per patient by region, 2006	93
Figure 5.24:	Therapeutic areas for Russian CRO trials (2006)	117
Figure 6.25:	Virtual Pharma R&D Model	131
Figure 6.26:	Virtual Pharma Inter-relationships	132
Figure 6.27:	Chorus Time & Cost Savings to Proof-of-Concept	134
Figure 6.28:	VDDI Pharmaceutical R&D Model	138
Figure 7.29:	Benefits of R&D spin offs	145
Figure 7.30:	Esperion's rebirth	149
Figure 8.31:	AstraZeneca's R&D Timeline	161
Figure 8.32:	AstraZeneca's Productivity gains	162
Figure 8.33:	The Evolution of GSK's R&D Model	164
Figure 8.34:	Complexity of the R&D process	166
Figure 8.35:	Pfizer's R&D Timeline	169
Figure 8.36:	Roche's Decision Making R&D process	171
Figure 8.37:	Roche's R&D Timeline	172
Figure 8.38:	Complexity of the R&D process	175
Figure 8.39:	Increased collaboration within the industry	177
Figure 8.40:	Shift in R&D focus and attrition rates	178
Figure 8.41:	Shift in therapeutic focus	180
Figure 8.42:	Recent biopharma deals	181
Figure 8.43:	Fragmentation of the industry	183
Figure 8.44:	The Future of R&D – Fully-Integrated Networked Pharmaceutical Companies	186

# List of Tables

Table 2.1:	PPPs – public and industry partners	38
Table 2.2:	R&D costs of PPP projects	39
Table 3.3:	Approved medicines developed through CRADA research	57
Table 3.4:	Recent CRADA projects under development	59
Table 3.5:	Recent CRADA projects under development (continued)	60
Table 4.6:	Advantages & disadvantages of CROs based on geography	75
Table 4.7:	Leading International CROs	77
Table 5.8:	Leading R&D Players in China	98
Table 5.9:	Leading R&D Players in India	108
Table 5.10:	Leading R&D Players in Russia	119
Table 6.11:	Virtual Pharma & Technology Aggregators	129
Table 6.12:	Examples of Therapeutic Switching	140
Table 7.13:	Recent pharma R&D spin offs	147
Table 7.14:	Recent CRO R&D Spin offs	152
Table 8.15:	AstraZeneca Recent R&D Activities	163
Table 8.16:	GlaxoSmithKline's recent R&D acquisitions	166
Table 8.17:	GlaxoSmithKline's recent strategic research collaborations	167
Table 8.18:	Simplified R&D Organization at Pfizer	168
Table 8.19:	Pfizer's Recent R&D Activities	170
Table 8.20:	Roche's Recent R&D Activities	173

